ClinicalTrials.gg
CompletedNCT05469126Updated May 27, 2026Results posted

A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants

A Phase 1 interventional study of LY3502970 and Clarithromycin in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
21 Years to 70 Years
Sex
All
01

Study summary

The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with clarithromycin in healthy participants. This study will last up to approximately 85 days for each participant.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation
  • Participants with a body weight of 45 kilograms (kg) or more and (BMI) within the range of 18.5 to 35.0 kilograms per meter squared (kg/m²)
  • Participants who have a level of at least 11.4 grams/deciliter (g/dL) for female participants and at least 12.5 g/dL for male participants
  • Male participants who agree to use highly effective/effective methods of and female participants not of

Exclusion criteria

Exclusion Criteria:

  • Participants who have a significant history of or current cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
  • Participants who regularly use known drugs of abuse
  • Women who are lactating and who are of
  • Participants who have known allergies to LY3502970, related compounds, or any components of the formulation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    LY3502970 alone (Period 1)

    Participants received a single 3 milligram (mg) dose of LY3502970 administered orally on Day 1. Participants were fasted overnight and remained in a fasted state for 4 hours after taking the study drug.

    Drug: LY3502970

  • Experimental
    Clarithromycin + LY3502970 (Period 2)

    Participants received below: Day 15 to 31: 500 mg of clarithromycin administered orally every 12 hours (Q12H). Day 21: 500 mg clarithromycin followed by 3 mg LY3502970 administered orally. Participants fasted overnight and remained in a fasted state for 4 hours after taking the study drug. Clarithromycin was administered 1 hour prior to LY3502970 dose administration, and a subsequent clarithromycin dose was administered 12 hours later

    Drug: LY3502970 · Drug: Clarithromycin

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Infinity AUC(0-∞) of LY3502970

    PK: AUC(0-∞) of LY3502970 is reported.

    Time frame: Period 1: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours Day 1 postdose; Period 2: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 168 and 240 hours Day 21 postdose

  2. PK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of LY3502970

    PK: AUC(0-tlast) of LY3502970 is reported.

    Time frame: Period 1: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours Day 1 postdose; Period 2: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 168 and 240 hours Day 21 postdose

  3. PK: Maximum Observed Concentration (Cmax) of LY3502970

    PK: Cmax of LY3502970 is reported.

    Time frame: Period 1: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours Day 1 postdose; Period 2: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 168 and 240 hours Day 21 postdose

07

Results

Posted May 27, 2026

Participant flow

LY3502970 Alone (Period 1)
Participant flow — LY3502970 Alone (Period 1)
Milestone3 mg LY3502970 (Day 1) and 500 mg Clarithromycin Q12H + 3 mg LY3502970 (Day 21)
Started26
Received at least one dose of study drug26
Completed21
Not completed5
Withdrew: Adverse event5
Clarithromycin + LY3502970 (Period 2)
Participant flow — Clarithromycin + LY3502970 (Period 2)
Milestone3 mg LY3502970 (Day 1) and 500 mg Clarithromycin Q12H + 3 mg LY3502970 (Day 21)
Started21
Received at least one dose of study drug21
Completed21
Not completed0

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Infinity AUC(0-∞) of LY3502970

PK: AUC(0-∞) of LY3502970 is reported.

Time frame:
Period 1: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours Day 1 postdose; Period 2: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 168 and 240 hours Day 21 postdose
Reported as:
Geometric least squares mean · nanogram*hour per milliliter (ng*hr/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Infinity AUC(0-∞) of LY3502970
nanogram*hour per milliliter (ng*hr/mL)LY3502970 (Day 1)Clarithromycin + LY3502970 (Day 21)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Infinity AUC(0-∞) of LY3502970380 ± 401380 ± 31
Statistical analysis
  • LY3502970 (Day 1) vs Clarithromycin + LY3502970 (Day 21) · Geometric ls mean ratio: 3.54 · 90% CI 2.96 to 4.22The least square means (LSMs) and differences in LSMs were back transformed to produce the geometric least square means (GLSMs) and ratio between GLSMs.
PrimaryPK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of LY3502970

PK: AUC(0-tlast) of LY3502970 is reported.

Time frame:
Period 1: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours Day 1 postdose; Period 2: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 168 and 240 hours Day 21 postdose
Reported as:
Geometric least squares mean · ng*h/ mL
PK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of LY3502970
ng*h/ mLLY3502970 (Day 1)Clarithromycin + LY3502970 (Day 21)
PK: Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)] of LY3502970333 ± 371270 ± 30
Statistical analysis
  • LY3502970 (Day 1) vs Clarithromycin + LY3502970 (Day 21) · Geometric ls mean ratio: 3.69 · 90% CI 3.19 to 4.28The least square means (LSMs) and differences in LSMs were back transformed to produce the geometric least square means (GLSMs) and ratio between GLSMs.
PrimaryPK: Maximum Observed Concentration (Cmax) of LY3502970

PK: Cmax of LY3502970 is reported.

Time frame:
Period 1: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours Day 1 postdose; Period 2: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96, 120, 168 and 240 hours Day 21 postdose
Reported as:
Geometric least squares mean · nanograms per milliliter (ng/mL)
PK: Maximum Observed Concentration (Cmax) of LY3502970
nanograms per milliliter (ng/mL)LY3502970 (Day 1)Clarithromycin + LY3502970 (Day 21)
PK: Maximum Observed Concentration (Cmax) of LY350297015.4 ± 3830.4 ± 30
Statistical analysis
  • LY3502970 (Day 1) vs Clarithromycin + LY3502970 (Day 21) · Geometric ls mean ratio: 1.88 · 90% CI 1.61 to 2.19The least square means (LSMs) and differences in LSMs were back transformed to produce the geometric least square means (GLSMs) and ratio between GLSMs.

Adverse events

Collected over Baseline up to 43 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
3 mg LY35029700/26 (0%)0/26 (0%)23/26 (88.5%)
500 mg Clarithromycin Q12H0/21 (0%)0/21 (0%)9/21 (42.9%)
500 mg Clarithromycin Q12H + 3 mg LY35029700/21 (0%)0/21 (0%)21/21 (100%)
Most frequent other events
Showing 10 of 21
Most frequent other events
Event3 mg LY3502970500 mg Clarithromycin Q12H500 mg Clarithromycin Q12H + 3 mg LY3502970
Decreased appetiteMetabolism and nutrition disorders13/260/2110/21
VomitingGastrointestinal disorders11/260/2110/21
NauseaGastrointestinal disorders9/260/217/21
HeadacheNervous system disorders9/260/216/21
DizzinessNervous system disorders3/260/217/21
Abdominal distensionGastrointestinal disorders8/260/215/21
Catheter site erythemaGeneral disorders0/260/216/21
Catheter site bruiseGeneral disorders2/260/214/21
Catheter site painGeneral disorders0/260/214/21
DiarrhoeaGastrointestinal disorders1/262/213/21

Baseline characteristics

All participants who received at least one dose of the study drug.

Age, Continuous
Age, Continuous(years)Overall Participants
Mean44.9 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Overall Participants
Female3
Male23
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Participants
Hispanic or Latino0
Not Hispanic or Latino26
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Participants
American Indian or Alaska Native0
Asian26
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall Participants
Singapore26
08

Study locations

1 site
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Nov 2022, 3 months.

Results were first posted in May 2026, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2022
First posted
Jul 21, 2022
StartActual
Aug 1, 2022
Primary completionActual
Nov 3, 2022
CompletionActual
Nov 3, 2022
Results first posted
May 27, 2026
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05469126
Responsible party
Sponsor
First posted
Jul 21, 2022
Start date
Aug 1, 2022
Primary completion
Nov 3, 2022
Completion
Nov 3, 2022
Results posted
May 27, 2026
Last update
May 27, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion